Sarepta Therapeutics (NASDAQ:SRPT) Given New $18.00 Price Target at Piper Sandler

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its target price lowered by Piper Sandler from $32.00 to $18.00 in a note issued to investors on Monday,Benzinga reports. The brokerage currently has a "neutral" rating on the biotechnology company's stock. Piper Sandler's price target would suggest a potential upside of 33.75% from the company's current price.

SRPT has been the subject of several other reports. UBS Group decreased their price objective on shares of Sarepta Therapeutics from $188.00 to $85.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Evercore ISI cut shares of Sarepta Therapeutics from an "outperform" rating to an "inline" rating and set a $50.00 price objective for the company. in a research report on Thursday, May 8th. Royal Bank Of Canada reduced their price objective on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a "sector perform" rating for the company in a research report on Thursday. Bank of America reduced their target price on shares of Sarepta Therapeutics from $28.00 to $20.00 and set a "neutral" rating for the company in a research report on Friday. Finally, Scotiabank upgraded shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price target on the stock in a research report on Friday, June 6th. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, Sarepta Therapeutics has a consensus rating of "Hold" and a consensus target price of $53.50.

Sarepta Therapeutics Stock Down 4.4%

Shares of NASDAQ SRPT traded down $0.62 during midday trading on Monday, reaching $13.46. 10,444,359 shares of the company's stock traded hands, compared to its average volume of 2,740,586. The stock's 50 day simple moving average is $28.42 and its 200-day simple moving average is $67.58. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a one year low of $11.95 and a one year high of $150.48. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -5.06 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analysts' expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm's quarterly revenue was up 80.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.73 EPS. On average, analysts predict that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Large investors have recently bought and sold shares of the company. Capital International Investors increased its holdings in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. Norges Bank acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter worth approximately $126,315,000. Assenagon Asset Management S.A. boosted its position in shares of Sarepta Therapeutics by 438.0% in the first quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company's stock worth $45,477,000 after acquiring an additional 580,123 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Sarepta Therapeutics by 27.9% in the first quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after acquiring an additional 577,848 shares during the last quarter. Finally, EcoR1 Capital LLC boosted its position in shares of Sarepta Therapeutics by 67.8% in the first quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock worth $82,480,000 after acquiring an additional 522,386 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.